What is the Epic Sciences AR-V7 test?
The Epic AR-V7 test identifies patients with truncated AR protein in the nucleus of circulating tumor cells (CTCs) within the blood. These patients may display resistance to an androgen directed therapeutic, such as Zytiga® or Xtandi®. Any patient facing a clinical decision regarding the utilization of Zytiga® or Xtandi® should be considered for this test.
This assay demonstrates specific nuclear localization of the AR-V7 biomarker through protein immunofluorescence evaluation and is proven to have significant clinical specificity and sensitivity using Epic Sciences’ no cell left behind platform. Initial prospective data has shown that the detection of the AR-V7 biomarker in a mCRPC (metastatic castration-resistant prostate cancer) patient informs the physician that the patient may have primary PSA (prostate-specific antigen) resistance with no potential benefit of receiving an androgen directed therapeutic. This additional information may enable the physician to triage the patient to a taxane chemotherapy which has been statistically shown to increase the patient’s overall survival (OS).
Genomic Health and Epic Sciences Collaboration to Deliver Novel AR-V7 Liquid Biopsy Test
How does the test work?
The test utilizes a blood sample, liquid biopsy, which is sent in to the Epic Sciences Clinical Laboratory.
Sample is processed for characterization of nuclear localized AR-V7+ CTCs in a CAP accredited and CLIA certified laboratory.
The patient results are reported to the ordering physician confirming the patient as either AR-V7+ or AR-V7-.
How do I receive more information?
To learn more about the Epic Sciences AR-V7 test and to review how to order please provide your contact information and one of our team members will contact you shortly.
Customer service is available Monday through Friday from 8am to 5pm pacific firstname.lastname@example.org